Biotron Limited

This article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article does not cite any sources. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (October 2014) (Learn how and when to remove this template message) This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (October 2014) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Biotron Limited (Biotron) is an Australian biotechnology company based in Sydney, NSW. Biotron develops novel small molecule antiviral therapeutics targeting Hepatitis C and HIV. Biotron has identified a new class of viral proteins as targets for potential intervention, and is developing novel small molecule therapeutics that target these proteins, specifically the p7 protein of Hepatitis C and Vpu protein of HIV.

BIT225[]

Biotron's lead drug, BIT225, is in clinical development for treatment of both HIV and Hepatitis C, as well as the hard to treat HIV/Hepatitis C co-infected population. It offers potential as a new class of oral direct-acting antiviral drug for Hepatitis C that may be used in combination with either current treatment strategies or with new classes of direct-acting antiviral drugs in development.